Reid Hoffman, a prominent figure in the tech world and co-founder of LinkedIn, has concluded his near decade-long tenure on Microsoft's board of directors. His decision marks a strategic pivot to dedicate his efforts to Manus, an innovative AI-driven company focused on biopharmaceutical and cancer drug discovery. This move highlights the increasing importance of artificial intelligence in advancing critical scientific research.

LinkedIn Co-Founder Embraces Startup Vision with Manus AI

In a significant development for the tech and biotech sectors, Reid Hoffman, the visionary behind LinkedIn, officially stepped down from Microsoft's board on June 6, 2026. This departure, which follows his prior resignation from OpenAI's board in 2023 due to potential conflicts of interest with his investment activities, signals a full commitment to his latest venture, Manus. On a recent episode of his podcast, “Possible,” featuring Microsoft CEO Satya Nadella, Hoffman articulated his motivation, stating that the substantial advancements at Manus necessitated his return to a founder-centric role. Manus, a pioneering biopharmaceutical and cancer drug discovery firm, is propelled by artificial intelligence. Co-founded by Hoffman, who also serves as its chairman, and supported by General Catalyst, the company boasts a leadership team that includes Dr. Siddhartha Mukherjee, a Pulitzer Prize-winning physician and author. Hoffman is particularly enthusiastic about Manus’s development of what he terms "Move 37" AI, a sophisticated form of machine intelligence designed to surpass human ingenuity in the realm of chemistry, specifically in the fight against cancer. This strategic realignment by Hoffman underscores a growing trend of experienced tech leaders channeling their expertise and resources into groundbreaking AI applications with profound societal implications.

Hoffman's unwavering dedication to Manus AI exemplifies the transformative power of focused innovation. His decision to leave a prestigious board position underscores the immense potential he sees in leveraging advanced AI to solve one of humanity's most pressing health challenges. This commitment serves as an inspiring example for entrepreneurs and investors alike, illustrating how cutting-edge technology, combined with a clear vision, can drive significant progress in fields traditionally marked by long development cycles and high failure rates. It also highlights the evolving landscape of technology, where AI is not just a tool for optimization but a catalyst for fundamental breakthroughs.